Manu Chakravarthy
Chief Tech/Sci/R&D Officer at Carmot Therapeutics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Heather Turner | F | 51 |
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 2 years |
| Timothy Kutzkey | M | 49 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 14 years |
| Stig Hansen | M | 59 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 16 years |
| Minako Pazdera | M | - |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 1 years |
| Charles Newton | M | 53 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 1 years |
| Kelly Boothe | M | - |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | - |
| Aetna Wun Trombley | M | 45 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 8 years |
| Jamere Jackson | M | 54 | 8 years | |
| Timothy Garnett | M | 63 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 2 years |
| Anne Phillips | M | 70 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 2 years |
| Timothy Garnett | - | - |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 2 years |
| Peter Svennilson | M | 62 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 4 years |
| Michael Gray | M | 53 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 1 years |
| Juan Luciano | M | 62 | 8 years | |
| David H. Schubert | M | - |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | - |
| Johna Norton | F | 57 | 7 years | |
| Heidi Brumbach | F | - |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 1 years |
| LeAnne Stewart | F | 59 |
Saint John's University
| 29 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John Lechleiter | M | 70 | 38 years | |
| Shreeram Aradhye | M | 62 | 3 years | |
| Robert Connelly | M | 63 | 5 years | |
| William Hinshaw | M | 55 | 5 years | |
| Paul Fehlner | M | 61 | 5 years | |
| Karen N. Horn | M | 80 | 29 years | |
| Franklyn Prendergast | M | 79 | 22 years | |
| Chip Baird | M | 52 | 5 years | |
| Joshua Smiley | M | 54 | 5 years | |
| Heidy Abreu King-Jones | F | 41 | - | |
| Shane Maltbie | M | 42 | 4 years | |
| Catherine Sohn | M | 71 | 4 years | |
| Jason Fredette | M | - | - | |
| Derica Rice | M | 59 | 14 years | |
| Christopher Viehbacher | M | 64 | 4 years | |
| Carolyn Bertozzi | M | 57 | 4 years | |
| Cristina Rondinone | M | 64 | 5 years | |
| Noubar Afeyan | M | 60 | 9 years | |
| Margaret Koziel | M | 64 | 4 years | |
| Stephen Mitchener | M | 45 | 2 years | |
| Tony Tramontin | M | 56 | 3 years | |
| Sheena Aurora | M | - | 4 years | |
| Stephen Curtis | M | - | 1 years | |
| Thomas W. Grein | M | 72 | 41 years | |
| Karen Lewis | F | - | 1 years | |
| Lori Macomber | F | 53 | 7 years | |
| Gary He | M | - | 12 years | |
| Jeremy Morgan | M | - | 3 years | |
| Anthony Iannazzo | M | - |
Saint John's University
| 4 years |
| Erika Jones | F | 39 | 3 years | |
| Trafford Clarke | M | 66 | - | |
| Jane Smith | F | - | 3 years | |
| Wen Hao Wang | M | 51 |
Saint John's University
| 4 years |
| Richard Gaynor | M | 74 | 14 years | |
| Michael Andriole | M | 51 | 16 years | |
| John Russo Tieri | M | - |
Saint John's University
| 5 years |
| Derek Schoenhofen | M | - |
Saint John's University
| 4 years |
| Charles Cooney | M | 80 | 7 years | |
| Peter Hutt | M | 89 | 4 years | |
| Thomas Fred Musmanno | M | 55 |
Saint John's University
| 2 years |
| Laurent Chardonnet | M | 59 | 2 years | |
| Patricia Martin | F | 63 | 26 years | |
| Fionnuala M. Walsh | M | 64 | 29 years | |
| David Epstein | M | 62 | 5 years | |
| Bronwen Mantlo | M | - | 4 years | |
| Barton Peterson | M | 65 | 8 years | |
| Jullian Jones | M | - | 4 years | |
| Rachel Humphrey | M | 62 | - | |
| Levi Garraway | M | - | 2 years | |
| Ivana Magovcevic-Liebisch | M | 55 | 1 years | |
| Christi L. Shaw | F | 57 | 2 years | |
| Jim Stellakis | M | - |
Saint John's University
| 4 years |
| Thomas Leggett | M | 47 | 2 years | |
| Mark Andersen | M | 53 | 11 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 72 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Manu Chakravarthy
- Personal Network
